New Delhi: Vaccine maker Bharat Biotech on Monday said it has commenced exports of Covid-19 vaccine Covaxin, and long-pending export orders have been executed during November. “Long pending export orders have been executed during November, to be further expanded during the following months. With the number of countries that have granted emergency use approvals for Covaxin increasing, exports to additional countries will also commence from December,” Bharat Biotech said in a tweet.
The company, however, did not provide details about the countries to which exports have commenced or about the additional countries to which the exports will start from December.
“Bharat Biotech thanks the Government of India for approving exports. Covaxin will now become an integral part of the global fight against this pandemic,” the tweet said.
Earlier last week, vaccine major Serum Institute of India had said that it has resumed exports of its vaccine Covishield to the international vaccine sharing programme COVAX.
COVAX is a multilateral initiative, led by the Global Vaccine Alliance, WHO, and the Coalition for Epidemic Preparedness Innovations, aimed to provide Covid-19 vaccines to all countries. Doses from Serum Institute of India for COVAX are dedicated to 92 lower-income countries.
While Serum Institute of India did not share the exact number of doses it shipped, it hopes to increase shipments substantially into the first quarter of 2022. It also plans to include Novavax Inc’s shot in its export kitty.
(With Inputs from ANI)